Small molecule · Inhibitor of ribonucleotide reductase
Fosgemcitabine palabenamide is a phosphoramidate prodrug of gemcitabine that is converted inside cells into difluorodeoxycytidine diphosphate and triphosphate. The diphosphate inhibits ribonucleotide reductase, while the triphosphate is incorporated into DNA, terminating DNA replication and inducing apoptosis. It is studied in ovarian cancer and biliary tract cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04163900 | Phase 3 | Biliary Tract Cancer | Terminated | NCNA |
| NCT03146663 | Phase 2 | Ovarian Cancer | Terminated | NCNA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Biliary Tract CancerOvarian Cancer
Updated Oct 25, 2026.